PharmAla Forms Partnership with Mt. Sinai Hospital
PharmAla Biotech Holdings Inc. (CSE: MDMA) is thrilled to announce that it has entered into a contract to provide its GMP LaNeo™ MDMA for a critical clinical trial at Mt. Sinai Health System. This development marks a significant step forward in the availability of clinical-grade MDMA for research and therapeutic applications.
Commitment to High-Quality Research
CEO Nicholas Kadysh expressed the company's enthusiasm for collaborating with the esteemed researchers at Mt. Sinai. He highlighted the institution's outstanding reputation for conducting significant work for the Veterans Affairs administration and its state-of-the-art facilities, which are pivotal for MDMA-assisted therapy. Kadysh conveyed PharmAla's dedication to ensuring that they meet both current and future needs for GMP MDMA drug products.
Improving Access to Drug Product Information
In an effort to transparentize the process, PharmAla has launched a new online tool that offers researchers direct access to essential drug product quality information. This resource, available on PharmAla’s website, is designed to facilitate the transition of clinical trial registrations and IRB approvals into the LaNeo MDMA Chemistry, Manufacturing, and Control package, thereby streamlining research processes.
Changes in Distribution Partnerships
Recently, PharmAla Biotech announced the termination of its supply agreement with CCrest Labs. This decision came as part of a strategy to optimize distribution channels. CCrest had been responsible for distributing PharmAla’s MDMA under the Special Access Program since 2022. However, with this change, PharmAla intends to rely on other distributors to continue facilitating patient access to MDMA therapy.
PharmAla's Commitment to Innovation
PharmAla Biotech is uniquely positioned within the biotechnology field, focusing on the research, development, and manufacturing of MDXX class molecules, including MDMA. The organization stands out as the only company currently providing clinical-grade MDMA for patient treatments outside of clinical trials. In addition, PharmAla is dedicated to advancing several intellectual property families, such as ALA-002, its leading drug candidate.
Building Regulatory Relationships
Founded on the principle that success in the psychedelics industry is contingent on strong partnerships with regulators, PharmAla aims to pave the way for ethical and responsible drug development. This regulatory-first approach is fundamental to the company's vision of alleviating the backlog of generic, clinical-grade MDMA to ensure prompt and effective access for therapeutic needs.
Contact Information
For more details regarding this partnership or for any inquiries, interested parties may reach out to Nicholas Kadysh, Chief Executive Officer of PharmAla Biotech Holdings Inc. He can be contacted via email at press@PharmAla.ca or by phone at 1-855-444-6362. More information can be found on their official website at www.PharmAla.ca.
Frequently Asked Questions
What is the purpose of PharmAla's partnership with Mt. Sinai?
The partnership is established to supply GMP LaNeo™ MDMA for clinical trials focused on MDMA-assisted therapy.
What does the new online tool provide for researchers?
This tool offers direct access to drug product quality information to support researchers in their clinical trial processes.
What was the reason behind the termination of the contract with CCrest Labs?
The termination is part of PharmAla's strategy to optimize distribution channels and ensure the continued availability of their products.
What distinguishes PharmAla in the biotechnology sector?
PharmAla is recognized as the only company providing clinical-grade MDMA for patient treatments outside of clinical trials, and it has a strong focus on regulatory relationships.
How can someone get in touch with PharmAla for inquiries?
Inquiries can be made by contacting Nicholas Kadysh via email at press@PharmAla.ca or phone at 1-855-444-6362.
